Allergan Aesthetics to Present New Data at 2024 ASDS Conference

Allergan Aesthetics will be presenting new data at the 2024 American Society for Dermatologic Surgery (ASDS) conference, which is underway through October 20. The data will showcase efficacy, safety and patient-reported outcomes across its facial injectable portfolio.

Four of the 12 abstracts bring presented are Best of Cosmetic Abstracts. 

“Allergan Aesthetics has one of the most robust portfolios for aesthetics innovation and continues to lead the industry in innovation,” Sara Sangha, Head of US Aesthetics Medical Affairs at Allergan Aesthetics, said. “As the global aesthetic brand that medical providers and patients know and trust, our commitment to serving and growing the industry with new products, indications and appeal to diverse and new patients is advanced by the research and data presented at ASDS.” 

Two notable presentations include safety and patient-reported outcomes from a Phase 3 open-label extension of platysma band and patient satisfaction after receiving JUVEDERM VOLUMA XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21. 

Allergan Aesthetics is also hosting a thought-provoking conversation around social integrity in the aesthetics industry as featured in “Moving the Needle on Ethics,” the industry-first global collation of thought-leadership essays from Allergan Aesthetics. 

The conversation will be led by author Dr. Kavita Mariwalla, and feature expert voices including Dr. Evan Rieder, double-board-certified dermatologist and psychiatrist, Dr. DiAnne Davis, board-certified dermatologist and Dr. Fatima Fahs, board-certified dermatologist and social media expert as moderator.

Allergan said the panel will spark “an open dialogue focusing on the trends in social media usage to promote aesthetics products and procedures and the importance of ethical practices to industry integrity. 

For more information on the abstracts being presented, click here.